<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20160919029871N6</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-02-12</date_registration>
      <primary_sponsor>Guilan University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of recurrence and complications of pterygium surgery in patients underwent pterygium surgery</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of recurrence and complications of pterygium surgery in the inferior rotational conjunctival autograft compared with the superior rotational conjunctival autograft in patients underwent pterygium surgery -a randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-02-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/68132</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: If the patients meet the inclusion criteria, they will be randomly assigned to two groups A (patients who will undergo inferior rotational conjunctival autograft) and group B (patients who will undergo surgery using superior rotational conjunctival autograft) based on random blocks.
Patients will be randomly divided into 2 groups with quadruple blocks of 40 people and will be examined in a single-blind manner. Registration of participants and allocation to groups will be done by the resident.The block sequence list is kept in a sealed and sealed letter in the Ophthalmology Research Center, and after the research permission from the Ethics Committee, the envelope is opened at the beginning of the study and based on gradual referrals, the patients will be placed in A or B groups, Blinding description: Being placed in group A or B and the type of surgery with lower conjunctival autograft or upper conjunctival autograft will not be told to the patient.(The patient will not know how to be selected in the treatment groups).</study_design>
      <phase>N/A</phase>
      <hc_freetext>Pterygium.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: groups A (patients who will undergo inferior rotational conjunctival autograft) Best corrected visual acuity, clinical inflammation of the pterygium surgery site, the duration of corneal epithelial defect repair, the occurrence of possible complications of pterygium surgery on the 1st, 3rd, 7th and 30th days after the operation and the recurrence of the lesion during the 6-month follow-up are checked by slit lamp. 6 months of follow-up are recorded and compared in two groups. The day after surgery, group A will be treated with topical antibiotic drugs (Chloramphenicol0.5%) and topical steroid Betamethasone 0.1%) with a dose of four times a day. The dose is reduced for two months and then stopped. Intervention 2: Control group:  group B (patients who will undergo surgery using superior rotational conjunctival autograft) Best corrected visual acuity, clinical inflammation of the pterygium surgery site, the duration of corneal epithelial defect repair, the occurrence of possible complications of pterygium surgery on the 1st, 3rd, 7th and 30th days after the operation and the recurrence of the lesion during the 6-month follow-up are checked by slit lamp. 6 months of follow-up are recorded and compared in two groups.The day after surgery, group A will be treated with topical antibiotic drugs (Chloramphenicol0.5%) and topical steroid Betamethasone 0.1%) with a dose of four times a day. The dose is reduced for two months and then stopped.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is It is not yet known if there will be a plan to make this available</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Mitra Akbari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Eye Research Center, Amiralmomenin Hospital, 17 Shahrivar St, Rasht</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>41396-37459</zip>
        <telephone>+98 13 3323 6886</telephone>
        <email>mitra.akbari20@gmail.com</email>
        <affiliation>Guilan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Mitra Akbari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Eye Research Center, Amiralmomenin Hospital, 17 Shahrivar St, Rasht</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>41396-37459</zip>
        <telephone>+98 31 3323 6886</telephone>
        <email>mitra.akbari20@gmail.com</email>
        <affiliation>Guilan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with a Pterygium larger than 3 mm at horizontal width over the cornea on Slit-lamp exam who are candidates for surgery</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with previous pterygium recurrence
The size of the base of the pterygium in the limbus region is greater than 8 mm
Pregnant and breastfeeding patients
Patients suffering from systemic diseases such as diabetes
Patients with eye surface diseases such as keratitis, conjunctivitis and severe dry eyes
Patients with a background of eye surgery in the last 6 months</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>H11.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Pterygium of eye</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: groups A (patients who will undergo inferior rotational conjunctival autograft) Best corrected visual acuity, clinical inflammation of the pterygium surgery site, the duration of corneal epithelial defect repair, the occurrence of possible complications of pterygium surgery on the 1st, 3rd, 7th and 30th days after the operation and the recurrence of the lesion during the 6-month follow-up are checked by slit lamp. 6 months of follow-up are recorded and compared in two groups. The day after surgery, group A will be treated with topical antibiotic drugs (Chloramphenicol0.5%) and topical steroid Betamethasone 0.1%) with a dose of four times a day. The dose is reduced for two months and then stopped.</i_keyword>
      <i_keyword>Control group:  group B (patients who will undergo surgery using superior rotational conjunctival autograft) Best corrected visual acuity, clinical inflammation of the pterygium surgery site, the duration of corneal epithelial defect repair, the occurrence of possible complications of pterygium surgery on the 1st, 3rd, 7th and 30th days after the operation and the recurrence of the lesion during the 6-month follow-up are checked by slit lamp. 6 months of follow-up are recorded and compared in two groups.The day after surgery, group A will be treated with topical antibiotic drugs (Chloramphenicol0.5%) and topical steroid Betamethasone 0.1%) with a dose of four times a day. The dose is reduced for two months and then stopped.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pterygium Recurrence. Timepoint: 6 Months After Surgery. Method of measurement: Clinical Examination.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Best Corrected Visual Acuity. Timepoint: Day 1, 3, 7, 30 After Surgery. Method of measurement: Clinical Examination.</sec_outcome>
      <sec_outcome>Clinical Inflammation Grading At Operation Site. Timepoint: Day 1, 3, 7, 30 After Surgery. Method of measurement: Clinical Examination.</sec_outcome>
      <sec_outcome>Epithelial Defect Healing Time. Timepoint: Day 1, 3, 7, 30 After Surgery. Method of measurement: Clinical Examination.</sec_outcome>
      <sec_outcome>Possible Complication of Pterygium Surgery. Timepoint: Day 1, 3, 7, 30 After Surgery. Method of measurement: Clinical Examination.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Guilan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-11-23</approval_date>
        <contact_name>Ethics Committee of Guilan University of Medical Sciences</contact_name>
        <contact_address>Shahid Siadaty St., Namju St., Rasht Rasht Guilan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
